Evidence
Tirzepatide Beat Semaglutide Head to Head. What That Does and Does Not Settle.
SURMOUNT-5 randomised 751 adults with obesity to tirzepatide or semaglutide for 72 weeks at maximum tolerated doses. Tirzepatide produced greater weight and waist reduction — waist fell 18.4 cm against 13.0 cm — and fewer participants discontinued for gastrointestinal reasons, 2.7% against 5.6%. It is the only direct comparison, and it settles less than headlines suggest.
Key takeaways
- SURMOUNT-5 is the only randomised head-to-head trial of the two drugs.
- Tirzepatide produced greater weight and waist reduction at 72 weeks.
- Gastrointestinal discontinuation was lower with tirzepatide (2.7% vs 5.6%).
- The trial was open-label, and enrolled adults without type 2 diabetes.
- Superiority on weight does not establish superiority on cardiovascular outcomes.
| Trial | SURMOUNT-5 |
|---|---|
| Participants | 751 |
| Duration | 72 weeks |
| Waist reduction | -18.4 cm vs -13.0 cm |
| GI discontinuation | 2.7% vs 5.6% |
| Identifiers | NCT05822830 · PMID 40353578 · doi:10.1056/NEJMoa2416394 |
Why does a head-to-head trial matter so much here?
Before SURMOUNT-5, comparing these drugs meant placing SURMOUNT-1's figure beside STEP 1's — separate trials with different populations, eligibility criteria, and time periods. Differences between trial populations routinely produce effect gaps as large as the drug differences being investigated, which makes such comparisons close to uninformative however confidently they are presented.
Randomising the same population to both drugs and following them identically removes that problem. It is the only design that supports a superiority claim, and it is why this result carries weight the earlier cross-trial arithmetic never did.
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg (diabetes) | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
What does the result not settle?
Which drug a given person should take. Semaglutide carries cardiovascular-outcome evidence in specific populations that tirzepatide's outcome programme has not replicated in the same form. Insurance coverage differs between them and frequently decides what is actually accessible. Individual tolerability varies and cannot be predicted from group data.
The trial also enrolled adults with obesity without diabetes, so its result does not transfer directly to the diabetes population, where SURMOUNT-2 recorded meaningfully smaller weight effects.
| Question | What SURMOUNT-5 shows | What it does not show |
|---|---|---|
| Weight reduction | Tirzepatide superior at 72 weeks | Results in people with diabetes |
| Waist circumference | -18.4 cm vs -13.0 cm | Body-composition detail |
| Tolerability | Lower GI discontinuation with tirzepatide | That either drug is well tolerated by everyone |
| Cardiovascular outcomes | Nothing — not an endpoint | That tirzepatide reduces cardiovascular events |
| Blinding | Open-label design | That expectation played no role |
| Duration | 72 weeks | What happens over years |
How should this change a decision?
Modestly, and only in combination with everything else. If both drugs are equally accessible and equally affordable to you, this trial is a reason to discuss tirzepatide first with a prescriber. If one is covered by your plan and the other is not, coverage will likely dominate the decision — and a drug you can sustain outperforms a marginally more effective one you stop paying for.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide vs semaglutide.
- A change to FDA labelling or regulatory position affecting a statement above.
- A verified correction accepted through the corrections process.
- A material change to a captured price, term, or programme condition.
More from the journal: all pieces
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on tirzepatide beat semaglutide head to head. what that does and does not settle..
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 6 technical terms this page uses, including DOI, PMID, endpoint, maximum tolerated dose — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| endpoint | The outcome a trial is designed to measure. A primary endpoint is specified before the trial begins; secondary and exploratory endpoints carry progressively weaker inferential weight. |
| maximum tolerated dose | The highest dose an individual can take without unacceptable adverse effects. Trials frequently escalate to this point rather than to a fixed dose, which means participants in one arm may be taking different amounts. |
| open-label | A trial in which participants and investigators know which treatment is being given. SURMOUNT-5 was open-label, a genuine limitation, though weight is an objective measurement less vulnerable to expectation than a self-reported outcome. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
Frequently asked questions
Which is more effective for weight loss?
In SURMOUNT-5, the only head-to-head randomised trial, tirzepatide produced greater weight and waist reduction over 72 weeks.
Which is better tolerated?
Both cause gastrointestinal effects. Discontinuation because of them was lower with tirzepatide, 2.7% against 5.6%.
Does semaglutide have any advantage?
It carries cardiovascular-outcome evidence in specific populations that tirzepatide's programme has not replicated in the same form.
Does this apply if I have type 2 diabetes?
Not directly. The trial enrolled adults without diabetes; SURMOUNT-2 is the relevant trial for that population.
Was the trial blinded?
No, it was open-label, which is a genuine limitation — though weight is an objective measure.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.